Final analysis of CTN002 completed

Final analysis of CTN002 completed The final analysis of the clinical phase II study of GPG, CTN002, has now been completed. The primary efficacy analysis (number of virus copies in the blood) showed no clinical or statistical effect in any of the treatment groups. Only three of a total of 37 patients showed any significant decrease in the number of virus copies after 6 weeks of treatment. The development work concerning an analytical method for GPG and one of its active metabolites has proceeded according to plan. In preparation for future clinical work, Tripep will be performing a pharmacological study on pigs during the second quarter of 2002. The study will include a number of different dosage forms, as well as intravenously administered GPG. GPG's active metabolite will also be tested. It is estimated that the preliminary results from the pig study will be available during the summer of 2002. "The results from this study will provide answers to our questions concerning the uptake and elimination of GPG and should also provide an explanation for the CTN002 results," says Hans Möller, President and CEO of Tripep. "It will provide us with decisive information for how our future work on GPG should proceed," he concludes. For further information, please contact: Hans Möller, President and CEO, tel. +46-8-449 84 80, mobile: +46-708-15 16 89, e-mail: hans.moller@tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2002/04/05/20020405BIT00250/wkr0001.doc http://www.waymaker.net/bitonline/2002/04/05/20020405BIT00250/wkr0002.pdf